Elevation Point Wealth Partners LLC Cuts Position in Merck & Co., Inc. $MRK

Elevation Point Wealth Partners LLC lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 37.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,722 shares of the company’s stock after selling 23,870 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $3,356,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Chemung Canal Trust Co. raised its position in shares of Merck & Co., Inc. by 21.1% during the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after purchasing an additional 13,285 shares during the last quarter. First Pacific Financial increased its stake in Merck & Co., Inc. by 14.7% during the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co increased its stake in Merck & Co., Inc. by 9.6% during the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after buying an additional 18,187 shares in the last quarter. Caxton Associates LLP raised its holdings in shares of Merck & Co., Inc. by 23.3% during the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after acquiring an additional 7,458 shares during the last quarter. Finally, NEOS Investment Management LLC lifted its position in shares of Merck & Co., Inc. by 39.9% in the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock valued at $29,181,000 after acquiring an additional 99,074 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the completion of the transaction, the chief financial officer owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares of the company’s stock, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 320,176 shares of company stock worth $38,281,735. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Stock Down 0.3%

Shares of NYSE:MRK opened at $115.61 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The business has a fifty day moving average of $115.26 and a two-hundred day moving average of $99.68. The stock has a market cap of $285.84 billion, a P/E ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the business posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of research analyst reports. Guggenheim lifted their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Scotiabank raised their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a report on Thursday, December 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research report on Friday, February 13th. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Cantor Fitzgerald upped their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $126.81.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.